Home > Neurology > MS Virtual 2020 > Novel Treatment Directions > Modulating BTK-dependent inflammatory signalling in microglia

Modulating BTK-dependent inflammatory signalling in microglia


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Using the cuprizone-induced toxicity model, the role of Bruton’s tyrosine kinase (BTK) signalling in modulating inflammation in microglial cells was assessed [1]. Results showed that BTK-dependent inflammatory signalling in these cells can be modulated using brain-penetrant BTK inhibitors in vivo. This treatment may suppress microglia-driven neuroinflammation in MS progression. BTK is expressed in B-lymphocytes and monocytes/macrophages as well as in microglia. It is assumed to modulate the activity of both adaptive and innate immune cells. In B cells, BTK is centrally involved in the B-cell receptor signalling pathway, regulating proliferation, maturation, antigen presentation, and production of secreted immunoglobulins. The research that was reported focused on the possible role of BTK in regulating microglial deleterious inflammatory signalling. This role was evaluated applying immunohistochemistry, Western blotting, and RNA sequencing i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on